Fagron press release

Regulated information
Waregem (Belgium)/Rotterdam (Netherlands)[1], 4 August 2015

Disclosure of received notification

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification on 31 July 2015 from Consonance Capital Management concerning the acquisition of voting securities. The shareholding of Consonance Capital Management crossed the disclosure threshold of 3% through the acquisition of voting securities.

Based on the denominator of 31,667,794 (total number of voting rights) and the latest received notifications, the major shareholders of Fagron are:

	Number of shares	% of effective voting rights
Carmignac Gestion	2,463,267	7.78%
TIAA-CREF Asset Management LLC	1,635,681	5.17%
BNP Paribas Investment Partners SA	1,609,182	5.08%
Fidelity Management and Research (FMR LLC)	1,517,822	4.79%
Consonance Capital Management	961,391	3.04%

The original notification forms are available on the website investors.fagron.com.

Fagron profile

Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Jan Peeters
Chief Financial Officer
Tel. +32 475 44 24 75
jan.peeters@fagron.com

Marieke Palstra
Global Investor Relations Director
Tel. +31 6 10 316 464
marieke.palstra@fagron.com

[1] This press release was sent out by Fagron NV and Fagron BV